Full-Time

SAP Security Lead

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$160k - $220kAnnually

Senior, Expert

San Francisco, CA, USA

This is a hybrid position, which implies that the candidate will be required to work in-office for part of the week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
SAP Products

You match the following BridgeBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in Information Technology, Computer Science, or a related field
  • 8+ years of experience in SAP Security, with a strong background in S/4HANA Private Cloud Edition, Fiori, BTP, and Cloud IAG
  • Experienced in SAP GRC (Access Control and Process Control) design and implementation for Security
  • Experienced in running SAP vulnerability assessment tool used in CyberSecurity and audit and compliance activities
  • In-depth knowledge of SAP’s authorization concepts and security policies, focusing on role-based access, user administration, and compliance within private cloud environments
  • Proven experience in GxP or equivalent validated environments, with a commitment to maintaining compliance and security across SAP systems
  • Demonstrated capability to serve as a security solution architect, defining cloud security solutions and technical designs aligned with project needs and RFP requirements
  • Extensive experience with end-to-end SAP security project lifecycles, including workshops, UAT, regression testing, cutover, and hyper care
  • Familiarity with SAP’s Private Cloud Edition, along with the specific security and compliance nuances for cloud-hosted SAP systems
  • Strong understanding of SOX compliance, GXP compliance, and regulatory standards
  • Excellent communication and interpersonal skills to effectively collaborate with cross-functional teams and stakeholders
Responsibilities
  • Design and oversee the SAP authorization framework, emphasizing role-based access control, user and role types, and roles/activity groups across SAP S/4HANA Private Cloud, Fiori, BTP, and Cloud IAG
  • Advise and manage SAP Identity and Access Control and integration with overall IAM & SSO architecture
  • Apply advanced knowledge of SAP’s private cloud security model to manage user administration, ensuring appropriate levels of access while adhering to segregation of duties (SoD) standards
  • Collaborate with SAP and third-party vendors to ensure user access configurations align with SAP's best practices for Private Cloud Edition and are optimized for a cloud-based environment
  • Define, implement and maintain SAP security policies and procedures to support compliance with SOX, GxP, GDPR, and life sciences industry standards, ensuring all processes meet rigorous requirements for a validated environment
  • Develop metrics and dashboards, reporting on the effectiveness of policies, procedures and controls for all SAP Security platforms
  • Use SAP tools for access control, risk analysis, and remediation (RAR), applying SoD mitigation strategies specific to private cloud deployment
  • Advise supporting processes as the SAP security subject matter expert
  • Ensure audit readiness and establish protocols for continuous access review and regulatory compliance specific to SAP’s Private Cloud Edition, with a focus on GxP standards and validated environments
  • Serve as a security solution architect, defining SAP security strategies for a private cloud environment and supporting technical designs for cloud security functions
  • Assess and address security risks specific to SAP’s Private Cloud Edition, implementing scalable solutions that adhere to cloud security principles and meet complex business and regulatory requirements
  • Work closely with cloud operations teams to ensure secure configurations and compliance within the SAP private cloud infrastructure, proactively strengthening security postures
  • Deliver guidance, collaborate and partner with IT Security and Infrastructure team on SAP Cryptography, Key Management, and SAP Data Protection
  • Lead SAP security tasks across full lifecycle projects, from initial workshops and UAT to regression testing, cutover, and hypercare activities, ensuring projects meet both security and compliance needs in a validated environment
  • Establish governance processes for role-based access control and SAP’s Cloud IAG, driving periodic access reviews and certifications for continuous security monitoring
  • Partner with project teams and consultants to embed SAP security standards in new implementations, upgrades, and change management processes within a private cloud context
  • Implement a risk management framework for SAP private cloud security, identifying potential threats and defining response strategies to mitigate risks, especially in a validated GxP environment
  • Serve as the escalation point for SAP security incidents, conducting root-cause analysis, coordinating remediation, and refining protocols to strengthen security across SAP cloud environments
  • Actively monitor SAP security alerts and vulnerabilities, enhancing incident response processes tailored to cloud-based SAP architecture
  • Foster a security-first culture by engaging with cross-functional teams and embedding security best practices into daily operations
  • Act as a trusted advisor to business and IT stakeholders, guiding them on SAP security compliance in a cloud-based environment
  • Mentor and support team members, sharing expertise on SAP security and compliance best practices
Desired Qualifications
  • SAP Security certifications in S/4HANA Private Cloud, Fiori, and BTP
  • Experience with life sciences or pharmaceutical industry regulatory frameworks and security standards
  • Proficiency with SAP GRC and advanced SAP security tools, including experience with cloud-based identity governance

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on therapies for specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring treatments to market. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

1%

2 year growth

0%
The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

Access Market Intelligence
Dec 6th, 2024
Orsini and PANTHERx Rare Selected by BridgeBio as Pharmacy Partners for ATTRUBY

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, also announced that it was selected by BridgeBio for the distribution of Attruby (acoramidis).

PR Newswire
Nov 26th, 2024
Bridgebio Selects Pantherx® Rare Specialty Pharmacy For Distribution Of Attruby™ (Acoramidis)

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attruby™ (acoramidis), a high-affinity transthyretin (TTR) stabilizer for twice daily oral administration, approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).2,5. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes. "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy," said Rob Snyder, Executive Chair, PANTHERx® Rare Pharmacy

MarketBeat
Nov 24th, 2024
Jennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Jennison Associates LLC invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Business Wire
Sep 9th, 2024
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

BioSpace
Jul 10th, 2024
Alnylam Could Challenge Pfizer In Attr-Cm But Experts Want Full Data

Pictured (from left): Pfizer and Alnylam signs/Taylor Tieden for BioSpaceUnveiled late last month, topline results from a Phase III trial of Alnylam’s RNAi therapy Amvuttra in ATTR amyloidosis with cardiomyopathy are turning some heads. The treatment showed a statistically significant reduction in all-cause mortality and recurrent cardiovascular events.“I expected this readout to be positive, but this was extremely positive,” said Kostas Biliouris, director and equity research analyst at Bank of Montreal Capital Markets. “I think the results reflect the best-case scenario.”The initial results appear promising, but a clearer picture will emerge when the full data come out later this summer. Further details of the HELIOS-B study will be presented as an abstract at the European Society of Cardiology’s congress in London, taking place Aug. 30 to Sept. 2.Paul Matteis, head of the therapeutics research team at Stifel, told BioSpace that not having those details is one of the biggest open questions at the moment

Benzinga
Jul 5th, 2024
Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. BBIO ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on July 2, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 25 new employees in restricted stock units for an aggregate of 123,070 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the "Plan").The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases

ETF Daily News
May 30th, 2024
Norges Bank Makes New $46.84 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Norges Bank makes new $46.84 million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Labiotech
May 22nd, 2024
The Undruggable Cancer Target: Kras Inhibitors Move Ahead In The Clinic

Some of the deadliest cancer mutations occur in a gene called KRAS. Drugs that target this gene to stop cancer cells from growing further are known as KRAS inhibitors, which have been regarded as a step forward in cancer research.These drugs seem to hold clinical promise as, only recently, a spinout of California-based BridgeBio launched with $200 million to solely focus on the development of KRAS inhibitors. A phase 1 study for bbo-8520 is currently enrolling participants. Drugging the undruggableOver the last three decades, KRAS mutations were considered undruggable. The term undruggable refers to target sites (for a specific disease) lacking the ability to interact with other molecules including drugs. This posed a serious challenge when designing drugs to bind to KRAS mutations.Dr. Emiliano Calvo, director of Clinical Research at START Madrid-Centro Integral Oncológico Clara Campal (CIOCC) hospital in Spain, explained that KRAS proteins in particular, had a smooth surface with only few pockets for a drug to bind effectively